Rockefeller Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Rockefeller Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.6K	Hold	1,871	–	–	﹤0.01%	4366
2025 Q4	$3.01K	Hold	1,871	–	–	﹤0.01%	4221
2025 Q3	$5.11K	Buy	+1,871	New	+$6.22K	﹤0.01%	3866
2023 Q1	–	Sell	-3,771	Closed	-$2K	–	2021
2022 Q4	$2K	Hold	3,771	–	–	﹤0.01%	3532
2022 Q3	$1K	Hold	3,771	–	–	﹤0.01%	3661
2022 Q2	$1K	Hold	3,771	–	–	﹤0.01%	3893
2022 Q1	$2K	Buy	3,771 +1,900	+102%	+$4.07K	﹤0.01%	3574
2021 Q4	$4K	Hold	1,871	–	–	﹤0.01%	3323
2021 Q3	$5K	Hold	1,871	–	–	﹤0.01%	3152
2021 Q2	$7K	Buy	+1,871	New	+$6.3K	﹤0.01%	2903
2020 Q4	–	Sell	-413	Closed	-$1K	–	2840
2020 Q3	$1K	Buy	413 +157	+61%	+$1.38K	﹤0.01%	2444
2020 Q2	$3K	Sell	256 -167	-39%	-$1.73K	﹤0.01%	2202
2020 Q1	$3K	Buy	+423	New	+$3.29K	﹤0.01%	2069

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Rockefeller Capital Management's AKBA Position: Q1 2026 in Review

Rockefeller Capital Management held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 1,871 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4366.

Rockefeller Capital Management first reported a position in AKBA in Q1 2020 and has held it in 13 quarters since. The position peaked at $7K in Q2 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Rockefeller Capital Management held 1,871 shares of Akebia Therapeutics worth $2.6K as of Q1 2026.
Rockefeller Capital Management left its Akebia Therapeutics share count unchanged in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4366 holding.
Rockefeller Capital Management first reported a position in Akebia Therapeutics in Q1 2020 and has held it in 13 quarters since.
Rockefeller Capital Management's Akebia Therapeutics position peaked at $7K in Q2 2021.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.